Biotech Values

[DewDiligence]

Re: HCV market share

…GILD is claiming 60% of the U.S. [HCV] market. That's up a little.

Yes, it’s up—but the 60% figure refers to GILD’s patient share rather its dollar share of the US HCV market, and it might be rounded up a little from, say, 58% or 59%.

GILD first made this assertion at the JPM conference in January, so it’s not new news.

ABBV’s implicit HCV guidance for 4Q19 is $653-753M (#msg-152051042, #msg-152042361); hence, unless ABBV misses it guidance badly, worldwide Mavyret sales in 4Q19 ought to be higher than GILD’s $630M reported today.